Kristel M. Dorighi

This paper introduces Partita, a high-density CRISPRa platform for comprehensive gene activation studies, demonstrating its utility in identifying cancer dependencies and resistance pathways in vitro and in vivo.

The paper identifies synthetic lethality between POLE exonuclease deficiency and high aneuploidy in cancer cells, suggesting POLE inhibition as a therapeutic strategy for aneuploid tumors.

The paper introduces an enAsCas12a mouse model and associated libraries for efficient gene editing and screening, identifying drug resistance genes and enabling simultaneous gene knockouts and activations.

This paper develops a degron-modified Cas12a system to enable accurate single-cell detection of pre-crRNAs, enhancing Perturb-seq capabilities for multiplex guide expression.

The paper develops a scalable mutagenic base editor platform to identify drug-resistant variants in cancer genomes efficiently.

The paper shows that H3K4me1 retention in enhancers supports germline competence by maintaining enhancer accessibility and responsiveness during in vitro differentiation.